Surgery in the treatment of type 2 diabetes mellitus

Scandinavian Journal of Surgery

Volumn 104, Issue 1, 2015, Pages 40-47

  Maleckas, A ^a,b   Venclauskas, L ^b   Wallenius, V ^a   Lonroth H ^a   Fandriks L ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Bariatric surgery; Gastric bypass; Sleeve gastrectomy; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE BLOOD LEVEL;

ANALYSIS; BARIATRIC SURGERY; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; WEIGHT REDUCTION;

BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; WEIGHT LOSS;

EID: 84925336851     PISSN: 14574969     EISSN: 17997267     Source Type: Journal    
DOI: 10.1177/1457496914561140     Document Type: Article

References (87)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, Geneva, 1999.
2. Zimmet P: Diabetes epidemiology as a trigger to diabetes research. Diabetologia 1999;42:499–518.
3. Colditz GA, Willett WC, Rotnitzky A et al: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481–486.
4. Chan JM, Rimm EB, Colditz GA et al: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961–969.
5. Almdal T, Scharling H, Jensen JS et al: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422– 1426.
6. Hemmingsen B, Lund SS, Gluud C et al: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;(6):CD008143.
7. Inzucchi SE, Bergenstal RM, Buse JB et al: Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–1596.
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559.
9. Beulens JW, Patel A, Vingerling JR et al: Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: A randomised controlled trial. Diabetologia 2009;52:2027–2036.
10. Abraira C, Duckworth WC, Moritz T: Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: An interim report. Diabetes Obes Metab 2009;11:150–156.
11. Bonds DE, Miller ME, Bergenstal RM et al: The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
12. Zoungas S, Patel A, Chalmers J et al: Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410– 1418.
13. Wang Y, Rimm EB, Stampfer MJ et al: Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005;81:555–563.
14. Huxley R, James WP, Barzi F et al: Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008;9(Suppl. 1):53–61.
15. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863–870.
16. Unger RH: Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159–5165.
17. Sjostrom L: Review of the key results from the Swedish Obese Subjects (SOS) trial—A prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219–234.
18. Johansson K, Neovius M, Hemmingsson E: Effects of antiobesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;99:14–23.
19. Franz MJ, VanWormer JJ, Crain AL et al: Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755–1767.
20. Sjostrom L, Lindroos AK, Peltonen M et al: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.
21. Ribaric G, Buchwald JN, McGlennon TW: Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: A systematic review and meta-analysis. Obes Surg 2014;24:437–455.
22. Buse JB, Caprio S, Cefalu WT et al: How do we define cure of diabetes? Diabetes Care 2009;32:2133–2135.
23. Pournaras DJ, Aasheim ET, Søvik TT et al: Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 2012;99:100–103.
24. Buchwald H, Estok R, Fahrbach K et al: Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med 2009;122:248–256.
25. Dixon JB, O’Brien PE, Playfair J et al: Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA 2008;299:316–323.
26. Ikramuddin S, Korner J, Lee WJ et al: Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240–2249.
27. Mingrone G, Panunzi S, De Gaetano A et al: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577–1585.
28. Schauer PR, Kashyap SR, Wolski K et al: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–1576.
29. Schauer PR, Bhatt DL, Kirwan JP et al: Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med 2014;370:2002–2013.
30. American Diabetes Association: Standards of medical care in diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61.
31. Marsk R, Jonas E, Rasmussen F et al: Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986–2006 in Sweden. Diabetologia 2010;53:2307–2311.
32. Cui Y, Elahi D, Andersen DK: Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-enY gastric bypass. J Gastrointest Surg 2011;15:1879–1888.
33. Dalcanale L, Oliveira CP, Faintuch J et al: Long-term nutritional outcome after gastric bypass. Obes Surg 2010;20:181–187.
34. Brethauer SA, Aminian A, Romero-Talamás H et al: Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628–636.
35. Arterburn DE, Bogart A, Sherwood NE et al: A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013; 23:93–102.
36. Chikunguwo SM, Wolfe LG, Dodson P et al: Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254–259.
37. Romeo S, Maglio C, Burza MA et al: Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 2012;35:2613–2617.
38. Lee WJ, Chong K, Ser KH et al: Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: A randomized controlled trial. Arch Surg 2011;146:143–148.
39. Abd Ellatif ME, Abdallah E, Askar W et al: Long term predictors of success after laparoscopic sleeve gastrectomy. Int J Surg 2014;12:504–508.
40. 2): A prospective controlled study. Obes Surg 2011;21:880–888.
41. Ma RC, Chan JC: Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013;1281:64–91.
42. Kashyap SR, Bhatt DL, Wolski K et al: Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013;36:2175– 2182.
43. Olbers T, Björkman S, Lindroos A et al: Body composition, dietary intake, and energy expenditure after laparoscopic Roux-enY gastric bypass and laparoscopic vertical banded gastroplasty: A randomized clinical trial. Ann Surg 2006;244:715–722.
44. Keidar A, Hershkop KJ, Marko L et al: Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: A randomised trial. Diabetologia 2013;56:1914–1918.
45. Li JF, Lai DD, Ni B et al: Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Can J Surg 2013;56:E158–E164.
46. 2. Obes Surg 2011;21:1650–1656.
47. Ramón JM, Salvans S, Crous X et al: Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: A prospective randomised trial. J Gastrointest Surg 2012;16:1116– 1122.
48. Sánchez-Pernaute A, Herrera MA, Pérez-Aguirre ME et al: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). One to three-year follow-up. Obes Surg 2010;20:1720– 1726.
49. Praveen Raj P, Kumaravel R, Chandramaliteeswaran C et al: Is laparoscopic duodenojejunal bypass with sleeve an effective alternative to Roux en Y gastric bypass in morbidly obese patients: Preliminary results of a randomized trial. Obes Surg 2012;22:422–426.
50. De Paula AL, Macedo AL, Prudente AS et al: Laparoscopic sleeve gastrectomy with ileal interposition (“neuroendocrine brake”): Pilot study of a new operation. Surg Obes Relat Dis 2006;2:464–467.
51. Kelley DE, Wing R, Buonocore C et al: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77:1287–1293.
52. Yip S, Signal M, Smith G et al: Lower glycemic fluctuations early after bariatric surgery partially explained by caloric restriction. Obes Surg 2014;24:62–70.
53. Plourde CE, Grenier-Larouche T, Caron-Dorval D et al: Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. Obesity 2014;22:1838–1846.
54. Strader AD, Vahl TP, Jandacek RJ et al: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005;288:E447–E453.
55. Pournaras DJ, Osborne A, Hawkins SC et al: Remission of type 2 diabetes after gastric bypass and banding: Mechanisms and 2 year outcomes. Ann Surg 2010;252:966–971.
56. Peterli R, Wölnerhanssen B, Peters T et al: Improvement in glucose metabolism after bariatric surgery: Comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: A prospective randomized trial. Ann Surg 2009;250:234–241.
57. Valverde I, Puente J, Martín-Duce A et al: Changes in glucagonlike peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005;15:387–397.
58. Mason EE: Ileal transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg 1999;9:223–228.
59. Cummings BP, Strader AD, Stanhope KL et al: Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 2010;138:2437–2446.
60. Patriti A, Facchiano E, Annetti C et al: Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 2005;15:1258–1264.
61. Rubino F, Marescaux J: Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann Surg 2004;239:1–11.
62. Ellsmere JC, Thompson CC, Brugge WR et al: Endoscopic interventions for weight loss surgery. Obesity 2009;17:929–933.
63. De Jonge C, Rensen SS, Verdam FJ et al: Endoscopic duodenaljejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354–1360.
64. De Moura EG, Martins BC, Lopes GS et al: Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 2011;14:183–189.
65. Mithieux G. A novel function of intestinal gluconeogenesis: Central signaling in glucose and energy homeostasis. Nutrition 2009;25:881–884.
66. Troy S, Soty M, Ribeiro L et al: Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008;8:201–211.
67. Watanabe M, Houten SM, Mataki C et al: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484–489.
68. Shaham O, Wei R, Wang TJ et al: Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 2008;4:214.
69. Goldberg RB, Fonseca VA, Truitt KE et al: Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531–1540.
70. Fonseca VA, Rosenstock J, Wang AC et al: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479–1484.
71. Patti ME, Houten SM, Bianco AC et al: Serum bile acids are higher in humans with prior gastric bypass: Potential contribution to improved glucose and lipid metabolism. Obesity 2009;17:1671–1677.
72. Pournaras DJ, Glicksman C, Vincent RP et al: The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012;153:3613–3619.
73. Steinert RE, Peterli R, Keller S et al: Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. Obesity 2013;21:E660–E668.
74. Salminen S, Bouley C, Boutron-Ruault MC et al: Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80(Suppl. 1):S147–S171.
75. Ley RE, Turnbaugh PJ, Klein S et al: Microbial ecology: Human gut microbes associated with obesity. Nature 2006;444:1022– 1023.
76. Larsen N, Vogensen FK, van den Berg FW et al: Gut microbiota in human adults with type 2 diabetes differs from nondiabetic adults. PLoS One 2010;5:e9085.
77. Zhang H, DiBaise JK, Zuccolo A et al: Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009;106:2365–2370.
78. Liou AP, Paziuk M, Luevano JM Jr et al: Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41.
79. Cani PD, Geurts L, Matamoros S et al: Glucose metabolism: Focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab 2014;40:246–257.
80. Tominaga M, Eguchi H, Manaka H et al: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920–924.
81. Perry R, Baron A: Impaired glucose tolerance. Why is it not a disease? Diabetes Care 1999;22:883–884.
82. Zimmet P, Alberti K: The changing face of macrovascular disease in non-insulin dependent diabetes mellitus in different cultures: An epidemic in progress. Lancet 1997;350:S1–S4.
83. Carlsson LMS, Peltonen M, Ahlin S et al: Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695–704.
84. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–309.
85. Heart Outcomes Prevention Evaluation (HOPE) Study: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.
86. Ohkubo Y, Kishikawa H, Araki E et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117.
87. Heneghan HM, Cetin D, Navaneethan SD et al: Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013;9:7–14.